Jennison Associates’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,504,299
| Closed | -$37.8M | – | 568 |
|
|
2025
Q4 | $37.8M | Sell |
1,504,299
-2,843,756
| -65% | -$66.7M | 0.02% | 251 |
|
|
2025
Q3 | $98.4M | Buy |
4,348,055
+1,686,232
| +63% | +$39.3M | 0.06% | 136 |
|
|
2025
Q2 | $46.1M | Buy |
2,661,823
+184,292
| +7% | +$3.41M | 0.03% | 230 |
|
|
2025
Q1 | $54.2M | Sell |
2,477,531
-282,873
| -10% | -$7.81M | 0.04% | 207 |
|
|
2024
Q4 | $88.1M | Buy |
2,760,404
+939,289
| +52% | +$28.2M | 0.05% | 151 |
|
|
2024
Q3 | $52.5M | Sell |
1,821,115
-1,770,301
| -49% | -$65.6M | 0.03% | 218 |
|
|
2024
Q2 | $138M | Buy |
3,591,416
+350,903
| +11% | +$15.9M | 0.09% | 93 |
|
|
2024
Q1 | $190M | Sell |
3,240,513
-35,409
| -1% | -$2.26M | 0.13% | 72 |
|
|
2023
Q4 | $196M | Sell |
3,275,922
-266,287
| -8% | -$13.5M | 0.15% | 69 |
|
|
2023
Q3 | $135M | Buy |
3,542,209
+1,571,606
| +80% | +$69M | 0.11% | 84 |
|
|
2023
Q2 | $180M | Sell |
1,970,603
-642,164
| -25% | -$55.4M | 0.15% | 72 |
|
|
2023
Q1 | $172M | Buy |
2,612,767
+97,450
| +4% | +$5.62M | 0.16% | 75 |
|
|
2022
Q4 | $130M | Sell |
2,515,317
-19,395
| -0.8% | -$1.03M | 0.13% | 97 |
|
|
2022
Q3 | $173M | Buy |
2,534,712
+236,365
| +10% | +$14M | 0.17% | 73 |
|
|
2022
Q2 | $104M | Sell |
2,298,347
-406,043
| -15% | -$18.5M | 0.1% | 110 |
|
|
2022
Q1 | $137M | Buy |
2,704,390
+842,233
| +45% | +$37.2M | 0.1% | 100 |
|
|
2021
Q4 | $88M | Sell |
1,862,157
-216,688
| -10% | -$8.53M | 0.06% | 137 |
|
|
2021
Q3 | $68.5M | Sell |
2,078,845
-370,679
| -15% | -$20.8M | 0.04% | 165 |
|
|
2021
Q2 | $155M | Sell |
2,449,524
-261,353
| -10% | -$13.5M | 0.1% | 89 |
|
|
2021
Q1 | $116M | Sell |
2,710,877
-61,543
| -2% | -$2.91M | 0.09% | 100 |
|
|
2020
Q4 | $159M | Sell |
2,772,420
-65,366
| -2% | -$2.76M | 0.11% | 76 |
|
|
2020
Q3 | $85.6M | Buy |
2,837,786
+710,708
| +33% | +$21.2M | 0.07% | 108 |
|
|
2020
Q2 | $69.5M | Buy |
2,127,078
+37,561
| +2% | +$1.21M | 0.06% | 121 |
|
|
2020
Q1 | $56M | Buy |
2,089,517
+984,486
| +89% | +$35M | 0.07% | 130 |
|
|
2019
Q4 | $33.8M | Buy |
1,105,031
+6,676
| +0.6% | +$185K | 0.03% | 237 |
|
|
2019
Q3 | $26.5M | Buy |
1,098,355
+175,111
| +19% | +$4.82M | 0.03% | 280 |
|
|
2019
Q2 | $23.4M | Buy |
923,244
+335,863
| +57% | +$6.83M | 0.02% | 322 |
|
|
2019
Q1 | $11.5M | Buy |
587,381
+457
| +0.1% | +$7.19K | 0.01% | 420 |
|
|
2018
Q4 | $7.74M | Buy |
586,924
+12,065
| +2% | +$185K | 0.01% | 455 |
|
|
2018
Q3 | $10.2M | Buy |
574,859
+4,395
| +0.8% | +$81.2K | 0.01% | 468 |
|
|
2018
Q2 | $12.6M | Buy |
570,464
+191,313
| +50% | +$4.4M | 0.01% | 452 |
|
|
2018
Q1 | $8.38M | Sell |
379,151
-227,774
| -38% | -$4.48M | 0.01% | 466 |
|
|
2017
Q4 | $13.2M | Buy |
+606,925
| New | +$8.93M | 0.01% | 445 |
|
Other funds holding APLS
ACA
PCM
DTC
Jennison Associates's APLS Position: Q1 2026 in Review
Jennison Associates sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 1,504,299 shares — an estimated $37.8M sold.
Jennison Associates first reported a position in APLS in Q4 2017 and held it in 33 quarters. The position peaked at $196M in Q4 2023. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.
- Jennison Associates reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Jennison Associates sold 1,504,299 Apellis Pharmaceuticals shares in Q1 2026, an estimated $37.8M.
- Jennison Associates first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 33 quarters.
- Jennison Associates's Apellis Pharmaceuticals position peaked at $196M in Q4 2023.
- 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.
Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.